Filing Flows › Foghorn Therapeutics (FHTX) › Q3 2026 › vs Q2 2026
Foghorn Therapeutics (FHTX) Q3 2026 vs Q2 2026 (quarter over quarter)
Foghorn Therapeutics's revenue rose $67.5M (+420%) from $16.1M in Q2 2026 to $83.5M in Q3 2026. Operating margin 67.8% against -54.8% (+122.6 pts).
Foghorn Therapeutics, Q3 2026: revenue $83.5M (+925% year over year), operating margin 67.8%, net earnings $58.1M, operating cash flow −$18.2M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 67.8% | -54.8% | +122.6 pts |
| Net margin | 69.6% | -44.7% | +114.3 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $83.5M | $16.1M | $67.5M | +420% |
| Other income, net | $1.5M | $1.6M | −$103K | -6% |
| Operating profit | $56.6M | −$8.8M | $65.4M | — |
| Costs & expenses | $26.9M | $24.9M | $2.0M | +8% |
| Pre-tax earnings | $58.1M | −$7.2M | $65.3M | — |
| Research & development | $18.8M | $18.5M | $313K | +2% |
| General & admin | $5.8M | $6.4M | −$558K | -9% |
| Net earnings | $58.1M | −$7.2M | $65.3M | — |
| Operating cash sources | $79.1M | $13.4M | $65.7M | +490% |
| Depreciation & amortization | $200K | $200K | $0 | 0% |
| Share-based compensation | $2.5M | $2.5M | −$30K | -1% |
| Cash used in operations | $18.2M | $17.8M | $399K | +2% |
| Working capital & other | $79.1M | $13.4M | $65.7M | +490% |
Questions
How much did Foghorn Therapeutics's revenue grow quarter over quarter in Q3 2026?
Foghorn Therapeutics's revenue rose $67.5M (+420%) from $16.1M in Q2 2026 to $83.5M in Q3 2026. Operating margin 67.8% against -54.8% (+122.6 pts).